CD19 and graft versus host disease: Since CD19 expression is absent in tissues targeted by GVHD, we can conclude that the indirect, immunomodulatory properties of Blinatumomab might be responsible for inducing it (Nägele et al., 2017; Khan and Gul, 2016).